Hexaxim H-W-2495

Name of the medicinal product Hexaxim
Opinion holder

Sanofi Pasteur
14 Espace Henry Vallee
69007 Lyon

Active substance diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin / poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) / hepatitis-B surface antigen / Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein
International non-proprietary name or common name diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)
Pharmacotherapeutic group Bacterial and viral vaccines combined
ATC code J07CA09
Therapeutic indication Hexaxim is indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b.
Orphan-medicinal-product designation date Not applicable

*This document includes:

Annex I - Summary of product characteristics
Annex IIA - Manufacturer responsible for batch release
Annex IIB - Recommendations to the opinion holder - conditions of use
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.


How useful was this page?

Add your rating
1 rating